Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M96,811Revenue $M36,247Net Margin (%)35.2Altman Z-Score2.1
Enterprise Value $M116,940EPS $5.3Operating Margin %43.2Piotroski F-Score6
P/E(ttm)6.8Beneish M-Score-1.7Pre-tax Margin (%)44.0Higher ROA y-yY
Price/Book13.210-y EBITDA Growth Rate %0.4Quick Ratio1.0Cash flow > EarningsN
Price/Sales2.85-y EBITDA Growth Rate %-5.1Current Ratio1.3Lower Leverage y-yY
Price/Free Cash Flow46.0y-y EBITDA Growth Rate %108ROA % (ttm)16.2Higher Current Ratio y-yY
Dividend Yield %6.1PEG--ROE % (ttm)145Less Shares Outstanding y-yN
Payout Ratio %39.0Shares Outstanding M2,435ROIC % (ttm)49.9Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKCharles Brandes 2015-12-31 Reduce-0.21%$39.1 - $43.53
($40.81)
$ 39.76-3%Reduce -7.92%4,303,030
GSKKahn Brothers 2015-12-31 Add0.2%$39.1 - $43.53
($40.81)
$ 39.76-3%Add 47.13%84,600
GSKJohn Rogers 2015-12-31 Add0.01%$39.1 - $43.53
($40.81)
$ 39.76-3%Add 1.29%1,476,976
GSKKen Fisher 2015-12-31 Add$39.1 - $43.53
($40.81)
$ 39.76-3%Add 0.03%11,531,673
GSKNWQ Managers 2015-12-31 Add$39.1 - $43.53
($40.81)
$ 39.76-3%Add 1.68%469,830
GSKTweedy Browne 2015-12-31 Reduce$39.1 - $43.53
($40.81)
$ 39.76-3%Reduce -0.25%133,124
GSKDodge & Cox 2015-12-31 Reduce$39.1 - $43.53
($40.81)
$ 39.76-3%Reduce -44.42%112,782
GSKDodge & Cox 2015-09-30 Reduce-0.46%$37.56 - $45.14
($41.64)
$ 39.76-5%Reduce -98.37%202,915
GSKCharles Brandes 2015-09-30 Add0.2%$37.56 - $45.14
($41.64)
$ 39.76-5%Add 8.33%4,673,082
GSKJohn Rogers 2015-09-30 Add0.12%$37.56 - $45.14
($41.64)
$ 39.76-5%Add 20.07%1,458,162
GSKHOTCHKIS & WILEY 2015-09-30 Add0.12%$37.56 - $45.14
($41.64)
$ 39.76-5%Add 6.76%12,400,884
GSKNWQ Managers 2015-09-30 Reduce-0.03%$37.56 - $45.14
($41.64)
$ 39.76-5%Reduce -9.49%462,055
GSKTweedy Browne 2015-09-30 Add0.01%$37.56 - $45.14
($41.64)
$ 39.76-5%Add 4.03%133,458
GSKJoel Greenblatt 2015-09-30 Reduce-0.01%$37.56 - $45.14
($41.64)
$ 39.76-5%Reduce -35.81%51,451
GSKKen Fisher 2015-09-30 Reduce$37.56 - $45.14
($41.64)
$ 39.76-5%Reduce -0.05%11,528,069
GSKJames Barrow 2015-09-30 Reduce$37.56 - $45.14
($41.64)
$ 39.76-5%Reduce -1.31%249,000
GSKKahn Brothers 2015-09-30 Reduce$37.56 - $45.14
($41.64)
$ 39.76-5%Reduce -1.20%57,500
GSKDodge & Cox 2015-06-30 Reduce-0.47%$41.65 - $48.23
($45.06)
$ 39.76-12%Reduce -46.76%12,476,998
GSKCharles Brandes 2015-06-30 Add0.23%$41.65 - $48.23
($45.06)
$ 39.76-12%Add 11.20%4,313,622
GSKHOTCHKIS & WILEY 2015-06-30 Reduce-0.11%$41.65 - $48.23
($45.06)
$ 39.76-12%Reduce -5.59%11,615,471
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$2280.73view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.1488.08view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29651.61view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12231.33view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14184view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12231.33view

Press Releases about GSK :

Quarterly/Annual Reports about GSK:

    News about GSK:

    Articles On GuruFocus.com
    Brandes Makes a Variety of Reductions in 4th Quarter Feb 11 2016 
    10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
    Stocks Bring High Dividend Yields to HOTCHKIS & WILEY Jan 14 2016 
    Jeff Auxier's Holdings Trading Below Peter Lynch Earnings Line Jan 04 2016 
    Cisco Systems, Microsoft and Intel Bring High Dividend Yields to First Eagle Investment Jan 04 2016 
    High Dividend Yield Ratios Are Hallmarks of Many Dodge & Cox Stakes Dec 21 2015 
    John Rogers' Holdings Trading Below Peter Lynch Earnings Line Dec 16 2015 
    3 Global Investment Ideas From Gurus Dec 10 2015 
    Dodge & Cox Sells Most of Stakes in Chevron, GlaxoSmithKline Nov 17 2015 
    3 Investment Ideas of Ariel Investment's Rupal Bhansali Nov 16 2015 

    More From Other Websites
    AstraZeneca’s Valuation Report Card: How Did It Score? Feb 12 2016
    GlaxoSmithKline Fined $54.3 Million for Preventing Generic Competition Feb 12 2016
    The tide may finally be turning against this contentious drug industry practice Feb 12 2016
    Should You Sell GlaxoSmithKline plc After It’s Been Fined And Buy AstraZeneca plc? Feb 12 2016
    Should You Sell GlaxoSmithKline plc After It's Been Fined And Buy AstraZeneca plc? Feb 12 2016
    GSK Fined £38m For 'Stifling' Drug Competition Feb 12 2016
    UK competition authorities fine GSK $54.5 million Feb 12 2016
    UK competition authorities fine GSK $54.5 million Feb 12 2016
    Watchdog fines GSK £37m for paying to keep generic drugs out of UK market Feb 12 2016
    UK watchdog fines GSK $54 million over 'pay-for-delay' drug deals Feb 12 2016
    UK watchdog fines GSK $54 mln over 'pay-for-delay' drug deals Feb 12 2016
    Glaxo Fined $54.3 Million in `Pay-for-Delay' Antitrust Probe Feb 12 2016
    UK watchdog fines GSK $54 mln over 'pay-for-delay' drug deals Feb 12 2016
    UK watchdog fines GSK $54 mln over 'pay-for-delay' drug deals Feb 12 2016
    Glaxo U.S. Pharma Head Says 'Unfettered Pricing' Days Are Gone Feb 11 2016
    Are GlaxoSmithKline plc, Ashmore Group plc & Henderson Group Plc Today’s Barnstorming Buys? Feb 11 2016
    Are GlaxoSmithKline plc, Ashmore Group plc & Henderson Group Plc Today's Barnstorming Buys? Feb 11 2016
    Why It Could Be The Perfect Time To Buy Rolls-Royce Holding PLC And GlaxoSmithKline plc Feb 10 2016
    GlaxoSmithKline Plc – Value Analysis (NYSE:GSK) : February 9, 2016 Feb 09 2016
    Alkermes CEO Richard Pops Isn't Giving Up On Breakthrough Depression Drugs Feb 09 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK